Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.
Arndt Vogel, MD, PhD
Advertisement
Arndt Vogel, MD, PhD, is a professor and clinician scientist in the Division of Gastroenterology and Hepatology at the University of Toronto.
Articles by Arndt Vogel, MD, PhD
Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.
Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.
Arndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Arndt Vogel, MD, discusses the goals of the IMMUTACE study investigating the efficacy of transarterial chemoembolization with nivolumab in patients with intermediate-stage hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Targeted Therapies Offer Hope for CholangiocarcinomaAugust 6th 2025
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
4
Investigating Novel Immunotherapy Targets in Metastatic RCC
5